In 2018, the National Institute on Aging - Alzheimer’s Disease Association (NIA-AA) formally proposed the diagnostic framework for AD based on the ATN criteria: A- confirmed by cerebrospinal fluid or Aβ-PET; T- confirmed by phosphorylated tau protein or tau-PET in cerebrospinal fluid; N- confirmed by total tau levels in cerebrospinal fluid, FDG-PET, or MRI brain atrophy (2, 71). Here, MAPT is linked to Brain atrophy.